Before continuing to this
website, please confirm
that you are a healthcare
professional.

YES
NO

You are now leaving this website The information the reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the respective company, or via the Consumer Medicine Information or Product Information.

Do you want to continue?

YES
It’s time to change the way we look at generalised myasthenia gravis (gMG)
“I can’t do the things I used to,
and that’s okay.”
~ GIGI, 40
Living with gMG
Model is not a real patient
Contact UCBCares for further information on gMG

of myasthenia gravis (MG) patients may have
uncontrolled and debilitating symptoms,
despite treatment with conventional therapies1–3

FIND OUT MORE ABOUT THE IMPACT OF gMG
Patients with uncontrolled gMG cope daily with debilitating moderate-to-severe symptoms and the ongoing risk of exacerbations despite being on treatment1–6

of refractory MG patients experienced at least one emergency hospital visit, were hospitalised overnight at least once or required a feeding tube over the course of 6 months3*

of MG patients experience a potentially life-threatening myasthenic crisis during their lifetime that requires mechanical ventilation3,7†

of patients do not reach complete
stable remission8,9‡

FIND OUT MORE ABOUT THE IMPACT OF gMG

UCB is a global biopharma company, inspired by the needs of people living with severe diseases

Our ambition is to advance the standard of care in gMG

At UCB, we create life-changing therapies for people with neurological conditions and have a decades-long record of innovation in neurology, including breakthrough product launches and philanthropic endeavours.10

We seek to elevate the patient care experience by offering well-designed clinical trials, innovative treatments and non-drug solutions that aim to provide personalised support for patients, when they need it most.10

UCB recently worked with patients along with clinical experts and regulatory agencies to develop the Myasthenia Gravis Symptoms Patient-Reported Outcome (MGSPRO), a novel PRO measure of real patients’ lived experiences with MG.11,12

Find out more about gMG

HOW DO YOU IDENTIFY UNCONTROLLED gMG?
WHAT CAUSES gMG?
Contact UCBCares for further information on gMG
*Visited an emergency room at least once (43.4% vs 27.1%), been hospitalised overnight at least once (32.9% vs 20.5%) or ever required a feeding tube (21.1% vs 9.1%) in refractory vs nonrefractory MG respectively, in a study of 825 patients (9.2% with refractory MG, 90.8% with nonrefractory MG), diagnosed with MG ≥2 years previously.3
†Case study report of 24 patients diagnosed with MG admitted with myasthenic crisis.7
‡In a study of 677 patients (76% with acetylcholine receptor [AChR]-positive MG, 8% with muscle-specific tyrosine kinase [MuSK]-positive MG and 16% with double negative [DN] MG), to assess rate of complete stable remission (CSR).9
AChR, acetylcholine receptor; CSR, complete stable remission; DN, double negative; gMG, generalised myasthenia gravis; MG, myasthenia gravis; MGSPRO, Myasthenia Gravis Symptoms Patient-Reported Outcome; MuSK, muscle-specific tyrosine kinase.

References

1. Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141–9.
2. Cutter G, Xin H, Aban I, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60(6):707–15.
3. Xin H, Harris LA, Aban IB, et al. Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a Myasthenia Gravis Foundation of America Patient Registry sample. J Clin Neurol. 2019;15(3):376–85.
4. Petersson M, Feresiadou A, Jons D, et al. Patient-reported symptom severity in a nationwide myasthenia gravis cohort : cross-sectional analysis of the Swedish GEMG study. Neurology. 2021;97(14):e1382–91.
5. Mendoza M, Tran C, Bril V, et al. Patient-acceptable symptom states in myasthenia gravis. Neurology. 2020;95(12):e1617–28.
6. Silva P. MG patients satisfied with treatment, but quality of life could be better, US survey shows. Myasthenia Gravis News. June 17, 2021. https://myastheniagravisnews.com/news-posts/2021/06/17/mg-patients-want-better-quality-of-life-us-survey-shows. Last accessed August 2024.
7. Werneck LC, Scola RH, Germiniani FM, et al. Myasthenic crisis: report of 24 cases. Arq Neuropsiquiatr. 2002;60(3–A):519–26.
8. Imai T, Utsugisawa K, Murai H, et al. Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. J Neurol Neurosurg Psychiatry. 2018;89(5):513–7.
9. Baggi F, Andreetta F, Maggi L, et al. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology. 2013;80(2):188–95.
10. UCB Integrated Annual Report 2023. https://www.ucb.com/sites/default/files/2024-03/2023_Full-Year_Integrated_Annual_Report-ENG_v3.pdf. Last accessed August 2024.
11. Regnault A, Morel T, de la Loge C, et al. Measuring overall severity of myasthenia gravis (MG): evidence for the added value of the MG Symptoms PRO. Neurol Ther. 2023;12(5):1573–90.
12. Cleanthous S, Mork A-C, Regnault A, et al. Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet J Rare Dis. 2021;16(1):457.